As a continuation of LLS Health’s legacy in developing innovative and reliable excipients, Apinovex and Apisolex polymers are novel excipients that overcome solubility challenges for oral and injectable drug formulations.
Lubrizol’s Apinovex™ polymers are high molecular weight polyacrylic acid excipients designed to enhance the solubility of BCS Class II and IV APIs and develop more efficient oral dosage forms with high, stable drug loading.
Lubrizol’s Apisolex™ GMP, injectable-grade excipient is a safe, polyamino acid-based polymer that enhances the solubility of BCS Class II and IV parenteral APIs by up to 50,000-fold.
Lubrizol is committed to providing best-in-class excipients and services that address solubility and bioavailability challenges. In this blog post, we discuss formulation tactics for BCS Class II and IV APIs and introduce Lubrizol’s novel solubility-enhancing excipients.
Read Our Blog
This webinar unveils two new polymer technologies from LLS Health for increasing drug solubility: oral-grade Apinovex™ and injectable-grade Apisolex™ polymers. Learn how these polymers enable scalable, reproducible manufacturing of drug products, intellectual property (IP) protection, and lifecycle management with 505(b)(2) filings.
Watch our Webinar